Replies to post #134556 on Biotech Values

[mcbio]

Yes that's correct. In my previous response to ghmm I noted that ECYT would be running a parallel trial to PROCEED using taxol but neglected to include what you just pointed out which is pretty important. There were some question marks as to whether the patient population would be FR++ so those details need to get ironed out.

Very interesting. Perhaps I've come around now on ECYT. ; )